Parametric Portfolio Associates’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Parametric Portfolio Associates’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-7,140	Closed	-$939K	–	4123
2020 Q4	$939K	Buy	7,140 +2,522	+55%	+$223K	﹤0.01%	3081
2020 Q3	$233K	Sell	4,618 -16,211	-78%	-$729K	﹤0.01%	3592
2020 Q2	$993K	Sell	20,829 -6,086	-23%	-$283K	﹤0.01%	2925
2020 Q1	$1.32M	Buy	26,915 +8,436	+46%	+$430K	﹤0.01%	2626
2019 Q4	$1.06M	Buy	+18,479	New	+$915K	﹤0.01%	3033
2019 Q3	–	Sell	-35,058	Closed	-$1.09M	–	4033
2019 Q2	$1.09M	Buy	+35,058	New	+$950K	﹤0.01%	3011

Parametric Portfolio Associates's EIDX Position: Q1 2021 in Review

Parametric Portfolio Associates sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 7,140 shares — an estimated $939K sold.

Parametric Portfolio Associates first reported a position in EIDX in Q2 2019 and held it in 6 quarters. The position peaked at $1.32M in Q1 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Parametric Portfolio Associates reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Parametric Portfolio Associates sold 7,140 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $939K.
Parametric Portfolio Associates first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2019 and held it in 6 quarters.
Parametric Portfolio Associates's Eidos Therapeutics, Inc. Common Stock position peaked at $1.32M in Q1 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Parametric Portfolio Associates's 13F filing for Q1 2021, filed 17 May 2021.